Danaher Corporation vs Invesco Preferred ETF — how do they compare? Danaher Corporation trades at $218.41 (market cap $152.87B), while Invesco Preferred ETF trades at $10.03 (market cap $3.60B). The key difference: Danaher Corporation is far larger — about 42.5× Invesco Preferred ETF's market cap, and Danaher Corporation pays a 0.74% dividend while Invesco Preferred ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Danaher Corporation for 69 Days and Invesco Preferred ETF for 94 Days on average.
| DHR | PGX | |
|---|---|---|
Market Cap | $152.87B | $3.60B |
Volume | 5,228,698 | 5,986,026 |
Sector | Health | — |
52-Week High | $242.05 | $11.61 |
52-Week Low | $161.91 | $9.97 |
Typical Hold Time | 69 Days | 94 Days |
Enterprise Value | $175.08B | — |
Dividend Yield | 0.74% | — |
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $218.49, up 1.36% on the day, with a bullish technical signal and consistent earnings beats in recent quarters. The stock shows strong profitability with a 58.51% gross margin and 15.95% net income margin, though revenue growth has been modest. Analyst consensus is strongly bullish with a $230.31 price target, supported by institutional buying activity and a recent dividend announcement.
The outlook for DHR is positive, driven by earnings momentum and institutional confidence, but risks include elevated valuation multiples and competitive pressures in the healthcare sector. Investors should weigh the strong analyst support against potential margin compression and macroeconomic headwinds affecting capital spending.
PGX trades at $9.97, down 0.89% today, with technical indicators showing a bearish trend from moving averages but oversold signals from the RSI. The stock faces pressure amid mixed sentiment, with key support and resistance levels clustered around $10. Recent corporate actions include scheduled dividends for July and September 2026, but fundamental data such as P/E and profitability metrics are unavailable for analysis.
The outlook for PGX is cautious due to the bearish technical setup and lack of current fundamental visibility. Risks include potential volatility near the $10 level and dependence on future financial disclosures to assess valuation. Investment opportunity hinges on upcoming earnings reports clarifying growth and margins, while sentiment remains divided amid limited recent news coverage.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →The fund generally will invest at least 80% of its total assets in the components of the index. Strictly in accordance with its guidelines and mandated procedures, ICE Data Indices, LLC selects securities for the index, which is a market capitalization-weighted index designed to measure the performance of the fixed rate US dollar-denominated preferred securities market.
Read more on PGX →